Recombinant Human Colony TtimulatingFactor 3 Receptor (Granulocyte)

• Cat.No.: CSF3R-3120H
• Product Overview: Recombinant Human CSF3R (extracellular domain, Met 1-Pro 621) with five aminio acids at the C-terminus, was expressed in Human cells.

Specification

• Cat. No.: CSF3R-3120H
• Description: Granulocyte Colony Stimulating Factor Receptor (G-CSFR) which belongs to the cytokine receptor superfamily, is a cell surface receptor for colony stimulating factor 3, a cytokine that plays a critical role in the regulation of the activation, proliferation, differentiation, and survival of the neutrophilic granulocyte lineage. This type I membrane protein has a composite structure consisting of an immunoglobulin(Ig)-like domain, a cytokine receptor-homologous (CRH) domain and three fibronectin type III (FNIII) domains in the extracellular region. G-CSFR mediates the specific effect of G-CSF through activating a variety of intracellular signaling cascades, including the Jak/Stat, PI3/Akt, Ras-Raf-MAP kinase, and Src family kinase pathways, and thus functions in defense against infection, inflammation and repair, and in the maintenance of steady state hematopoiesis.
• Purity: >95% as determined by SDS-PAGE.
• Endotoxin: < 1.0 EU per 1μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Glu 25
• Molecular Mass: The mature recombinant human G-CSFR consists of 63 amino acids and predicts a molecular mass of 69.0 KDa. As a result of glycosylation, the apparent molecular mass of rhG-CSFR is approximately 90-95KDa in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile PBS, pH 7.4 . Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage and usage. Avoid repeated freeze-thaw cycles.

Gene Information

• Gene Name: CSF3R colony stimulating factor 3 receptor (granulocyte) [ Homo sapiens ]
• Synonyms: colony stimulating factor 3 receptor (granulocyte); GCSFR; colony stimulating factor 3 receptor; antigenOTTHUMP00000009703; CSF3R; antigenOTTHUMP00000009704; CD114; antigenOTTHUMP00000009705; granulocyte colony stimulating factor receptor
• Gene ID: 1441
• mRNA Refseq: NM_000760
• Protein Refseq: NP_000751
• MIM: 138971
• UniProt ID: Q99062
• Chromosome Location: 1p35-p34.3
• Pathway: Cytokine-cytokine receptor interaction; Hematopoietic cell lineage; Jak-STAT signaling pathway; Pathways in cancer
• Function: cytokine receptor activity; otein binding; receptor activity

Reviews

06/23/2019

the CSF3R protein demonstrates exceptional stability, allowing for prolonged storage and usage without compromising its integrity.

12/07/2018

the protein's high quality ensures accurate and reliable results, enabling precise analysis and interpretation of experimental data.

09/16/2018

The manufacturer of the CSF3R protein plays a crucial role in supporting researchers during their trials.

Q&As

In which conditions are CSF3R-targeted therapies currently being investigated?

CSF3R-targeted therapies are under investigation for conditions such as chronic neutrophilic leukemia and other myeloproliferative neoplasms.

Are there specific diagnostic tests for CSF3R mutations?

Yes, genetic testing and sequencing techniques are commonly employed to identify CSF3R mutations and guide clinical decision-making.

How do CSF3R mutations impact the prognosis of hematological disorders?

The presence and specific type of CSF3R mutations can influence the prognosis of hematological disorders, guiding clinicians in predicting disease progression and response to treatment.

Can CSF3R mutations be hereditary?

Yes, some CSF3R mutations can be hereditary, leading to familial cases of neutropenia.

How does understanding CSF3R protein function contribute to treatment strategies?

Targeted therapies directed at CSF3R may offer more effective and tailored treatment options for patients with disorders related to abnormal granulocyte production.